Clinical Trial: NCT03716180
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.
The names study drugs involved in this study are:
- Paclitaxel (also called Taxol)
- Trastuzumab (also called Herceptin)
- Pertuzumab (also called Perjeta)
Official Title
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Paclitaxel
- Drug: Trastuzumab
- Drug: Pertuzumab
Other Study ID Numbers
- 18-394
Start Date (Actual)
2018-11-05
Primary Completion Date (Actual)
2020-10-08
Study Completion Date (Estimated)
2030-09-01
Enrollment (Actual)
100
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.
The names study drugs involved in this study are:
- Paclitaxel (also called Taxol)
- Trastuzumab (also called Herceptin)
- Pertuzumab (also called Perjeta)
Official Title
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Paclitaxel
- Drug: Trastuzumab
- Drug: Pertuzumab
Other Study ID Numbers
- 18-394
Start Date (Actual)
2018-11-05
Primary Completion Date (Actual)
2020-10-08
Study Completion Date (Estimated)
2030-09-01
Enrollment (Actual)
100
Study Type
Interventional
Phase
Phase 1